Tao Sun

ORCID: 0000-0001-8062-3432
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroscience and Neuropharmacology Research
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Epilepsy research and treatment
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Glioma Diagnosis and Treatment
  • Breast Cancer Treatment Studies
  • Neurological Disease Mechanisms and Treatments
  • Genetics and Neurodevelopmental Disorders
  • Cancer Immunotherapy and Biomarkers
  • Epigenetics and DNA Methylation
  • Receptor Mechanisms and Signaling
  • Radiomics and Machine Learning in Medical Imaging
  • Neuropeptides and Animal Physiology
  • Neurogenesis and neuroplasticity mechanisms
  • Lung Cancer Research Studies
  • Biochemical effects in animals
  • Menopause: Health Impacts and Treatments
  • Metabolomics and Mass Spectrometry Studies
  • Estrogen and related hormone effects
  • Monoclonal and Polyclonal Antibodies Research
  • Colorectal Cancer Treatments and Studies
  • MicroRNA in disease regulation

Liaoning Cancer Hospital & Institute
2016-2025

Capital Medical University
2023-2025

Beijing Anzhen Hospital
2023-2025

Dalian University of Technology
2023-2025

Beijing Institute of Water
2025

BeiGene (China)
2025

Fudan University
2025

Ningxia Medical University
2015-2024

China Medical University
2015-2024

Chinese Academy of Sciences
2013-2024

Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.

10.1056/nejmoa2203690 article EN New England Journal of Medicine 2022-06-05

It is more than 50 years since the lysosome was discovered. Since then its hydrolytic machinery, including proteases and other hydrolases, has been fairly well identified characterized. Among these are cysteine cathepsins, members of family papain-like proteases. They have unique reactive-site properties an uneven tissue-specific expression pattern. In living organisms their activity a delicate balance expression, targeting, zymogen activation, inhibition by protein inhibitors degradation....

10.1016/j.bbapap.2011.10.002 article EN cc-by-nc-nd Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2011-10-16

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic disease, but effects on specific cardiovascular outcomes are uncertain, as people without previous disease (primary prevention). Methods: In CREDENCE (Canagliflozin Renal Events Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants were randomly assigned to canagliflozin or placebo a background optimized standard care. Results: Primary prevention (n=2181,...

10.1161/circulationaha.119.042007 article EN cc-by-nc-nd Circulation 2019-07-11

Chronic subdural hematoma (CSDH) is a trauma-associated condition commonly found in elderly patients. Surgery currently the treatment of choice, but it carries significant risk recurrence and death. Nonsurgical treatments remain limited ineffective. Our recent studies suggest that atorvastatin reduces hematomas improves clinical outcomes patients with CSDH.To investigate safety therapeutic efficacy to nonsurgically treat CSDH.The Effect Atorvastatin on Subdural Hematoma (ATOCH) randomized,...

10.1001/jamaneurol.2018.2030 article EN JAMA Neurology 2018-07-30

BackgroundAmivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC).MethodsIn a phase 3, international, randomized trial, we assigned, 2:2:1 ratio, EGFR-mutated (exon 19 deletion L858R), locally metastatic NSCLC to receive amivantamab–lazertinib (in an open-label fashion),...

10.1056/nejmoa2403614 article EN New England Journal of Medicine 2024-06-26

Abstract This multicenter, phase II study (NCT03872791) aims to evaluate the efficacy and safety of anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with nab-paclitaxel in first-line treatment patients metastatic triple-negative breast cancer (TNBC). The primary endpoints included objective response rate (ORR) duration (DoR), secondary progression-free survival (PFS), overall (OS) rate, safety, correlation PD-L1 status clinical efficacy. trial met pre-specified endpoints. 27 female were...

10.1038/s41467-024-45160-y article EN cc-by Nature Communications 2024-02-03

Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes the CREDENCE trial. We assessed efficacy safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).CREDENCE randomly assigned 4401 participants an eGFR 30 to <90 ml/min per 1.73 m2 substantial albuminuria 100 mg or placebo. used Cox proportional hazards regression analyze effects on outcomes within screening subgroups (30 <45, 45 <60, 60 m2) linear mixed models slope.At screening, 1313...

10.1681/asn.2019111168 article EN public-domain Journal of the American Society of Nephrology 2020-04-24

Abstract Doxorubicin (DOX) is a wide-spectrum antitumor drug, but its clinical application limited by cardiotoxicity. However, the mechanisms underlying DOX-induced cardiomyopathy remain mostly unclear. Here we observed that apoptosis repressor with caspase recruitment domain (ARC) was downregulated in mouse heart and cardiomyocytes upon DOX treatment. Furthermore, enforced expression of ARC attenuated cardiomyocyte mitochondrial fission apoptosis. transgenic mice demonstrated reduced...

10.1038/cddis.2015.41 article EN cc-by Cell Death and Disease 2015-03-12

Cardiomyocyte death is an important reason for the cardiac syndromes, such as heart failure (HF) and myocardial infarction (MI). In diseases, necrosis one of main forms cell death. MicroRNAs (miRNAs) are a class small non-coding RNAs that mediate post-transcriptional gene silencing. Hitherto, it not yet clear whether miRNA can regulate in cardiomyocyte. this work, we performed microarray to detect miRNAs response H2O2 treatment, results showed miR-874 was substantially increased. We further...

10.1038/cddis.2013.233 article EN cc-by Cell Death and Disease 2013-07-04

Brain inflammation is one of the main causes epileptogenesis, a chronic process triggered by various insults, including genetic or acquired factors that enhance susceptibility to seizures. Amentoflavone, naturally occurring biflavonoid compound has anti-inflammatory effects, exerts neuroprotective effects against nervous system diseases. In present study, we aimed investigate amentoflavone on epilepsy in vivo and vitro elucidate underlying mechanism. The model BV2 microglial cellular were...

10.3389/fphar.2019.00856 article EN cc-by Frontiers in Pharmacology 2019-07-30

Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, South Africa. Methods: This randomized, double-blind, phase III study was conducted between 9 December 2016 29 March 2019. Postmenopausal HR-positive, HER2-negative ABC no prior systemic an setting (cohort A) or...

10.1177/1758835920963925 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2020-01-01

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however, almost all will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody immune cell-directing activity that targets activating and resistance mutations MET amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab combination lazertinib, a potent, brain-penetrant third-generation TKI, antitumor...

10.2217/fon-2021-0923 article EN Future Oncology 2021-12-16

To develop and validate a deep learning signature (DLS) from diffusion tensor imaging (DTI) for predicting overall survival in patients with infiltrative gliomas, to investigate the biological pathways underlying developed DLS.

10.1016/j.ebiom.2021.103583 article EN cc-by-nc-nd EBioMedicine 2021-09-23

Patients with epidemic infections caused by Neisseria meningitidis serogroup C were studied to assess the relationship of abnormal coagulation parameters prognosis. categorized into stages within first hour observation according severity illness. During years 1986 through 1991, 113 patients bacteriologically proven N. infection observed, 15 whom died. Purpura fulminans was seen in 28 patients, 14 (50%) Among surviving who had purpura fulminans, 10 suffered gangrene deforming autoamputation...

10.1093/clinids/17.2.254 article EN Clinical Infectious Diseases 1993-08-01

To determine the true community prevalence of human cystic (CE) and alveolar (AE) echinococcosis (hydatid disease) in a highly endemic region Ningxia Hui, China, by detecting asymptomatic cases.Using hospital records "AE-risk" landscape patterns we selected study communities predicted to be at risk Guyuan, Longde Xiji counties. We conducted surveys 4773 individuals from 26 villages 2002 2003 using questionnaire analysis, ultrasound examination serology.Ultrasound serology showed range...

10.2471/blt.05.025718 article EN cc-by Bulletin of the World Health Organization 2006-08-31

Epilepsy comorbidities and anti‑epileptic drugs (AEDs) are currently the main limitations of epilepsy treatment. Semaglutide is a glucagon like peptide‑1 analogue that has entered market as new once‑weekly drug for type II diabetes. The aim present study was to investigate functions semaglutide in inflammation models, order its potential mechanism. In vitro, an model established using lipopolysaccharide (LPS) nigericin stimulation BV2 cells. vivo, chronic mice were generated...

10.3892/ijmm.2021.5052 article EN cc-by-nc-nd International Journal of Molecular Medicine 2021-10-20
Coming Soon ...